drugset
drugset / Trial / NCT03309943

Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity

NCT03309943 ↗

Phase 4 Completed 44 enrolled Duke University National Institute on Drug Abuse (NIDA) · collabNational Institutes of Health (NIH) · collab
RandomizedParallel-groupTriple-blindBasic science

Summary

The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = 50) will take photographs of locations where they do and do not smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg) or placebo prior to completing: A) An MRI session assessing neural responses to personal smoking/non-smoking environments, standard smoking/non-smoking environments and proximal smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response to environmental cues.

Timeline

Start
2018-01-16
Primary completion
2019-07-15
Completion
2019-07-15

Outcome

Mixed primary results

registry MEAN Propranolol: Smoking: 6.103084 (Standard Deviation 1.618450) units on a scale NCT03309943 ↗

registry MEAN Placebo: Smoking: 6.547619 (Standard Deviation 1.685597) units on a scale NCT03309943 ↗

registry analysis (superiority test); Propranolol vs Placebo; p = .024; Repeated Measures ANCOVA NCT03309943 ↗

registry analysis (superiority test); Propranolol vs Placebo; p = .086; Repeated Measures ANCOVA NCT03309943 ↗

registry analysis (superiority test); Propranolol vs Placebo; p = .140; Repeated Measures ANCOVA NCT03309943 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 40 mg —

Indications

No indication recorded.